Navigation Links
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
Date:3/24/2010

Monthly dialogues replace annual reviews to give employees more ‘real time’ feedback. Employee development is a priority at Merrimack, which has hired 50 people since October 2009 and is a recipient of a $1.5 million Massachusetts Life Sciences Center tax incentive award for job creation.

Cambridge, Mass (PRWEB) March 24, 2010 -- Merrimack Pharmaceuticals was one of 18 winners out of more than 100 entries in Human Resources magazine’s second annual competition for the most noteworthy HR ideas. Awards were in four categories: Benefits, HR Technology, Talent Management and Training & Development.

Merrimack was recognized in the Talent Management category for the company’s decision last year to replace its semi-annual review process with 12 monthly employee dialogue sessions. “Talking monthly helps ensure that managers are actively involved in their employees’ development and creates alignment around team and company objectives,”    said Andy Porter, senior director of Human Resources, at Merrimack. “As Merrimack continues to grow, it’s critically important that we have a strong foundation of manager-employee feedback in place.” The dialogues include: goal check-in, job competencies and development, one actionable item the employee can improve, and types of support the manager can provide.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

###

Read the full story at http://www.prweb.com/releases/merrimackpharma/hraward/prweb3770804.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
7. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research ... (CTC) conference presented by The Conference Forum in Boston on April 3-4, 2017. ... to drive improved clinical trial outcomes and bring them closer to the patient. Clinical ...
(Date:3/27/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV), a precision medicine ... Bill Welch , will be presenting at this ... AM EDT at the Essex House in ... Scientific Officer, Mark Erlander , Ph.D., will also ... The presentation will be webcast live at ...
(Date:3/27/2017)... 2017 Neurotrope, Inc. (OTCQB: NTRP),  a ... diseases, including Alzheimer,s disease, today announced that it ... the Company,s common stock on the NASDAQ Capital ... Market, a unit of the NASDAQ OMX Group. ... Opening Bell at the NASDAQ MarketSite in Times ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March 24, ... Maxwell Biotech Venture Fund (MBVF), today announced positive results ... to the standard drug therapy regimen in patients with ... molecule drug discovered by scientists at Sequella, Inc. ( ... of Health. A total of 140 ...
Breaking Biology Technology:
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
Breaking Biology News(10 mins):